Ovarian Cancer
Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
Published in Cancer Weekly, March 25th, 2008
In this Phase 2 clinical trial, single agent SNS-595 has demonstrated disease control (defined as stable disease, partial response or complete response) in 31 of 35 patients evaluable for best response using GOG-RECIST criteria. Of these 31 patients, one patient had a complete response, four patients had partial responses...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2008-03-25)
More Articles from Cancer Weekly
- Phototherapy
Combined stenting and photodynamic therapy improves survival in late stage liver cancer patients - Ataxia Telangiectasia
Findings from M.L. Cortes and co-researchers advance knowledge in ataxia telangiectasia - Biologics
Raven biotechnologies Advances RAV18 Through Agreement With CMC ICOS Biologics - Cancer
Power3 Medical Products Inc. Publishes Discovery of Protein Biomarkers for Esophageal Malignancies in the International Journal of Cancer - Cancer Gene Therapy
New cancer gene therapy research has been reported by scientists at Oita University, Medical Department - Cancer Gene Therapy
Reports outline cancer gene therapy study results from Dankook University - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
